Evidence map›Paper›PMID 31104075›Full record

ArticleCancer immunology, immunotherapy : CII2019

Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.

Lindsey M Kuehm, Kyle Wolf, John Zahour, Richard J DiPaolo, Ryan M Teague

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lindsey M KuehmMolecular Microbiology and Immunology Department, Saint Louis University School of Medicine, 1100 South Grand Blvd, St. Louis, MO, 63104, USA.
Kyle WolfMolecular Microbiology and Immunology Department, Saint Louis University School of Medicine, 1100 South Grand Blvd, St. Louis, MO, 63104, USA.
John ZahourMolecular Microbiology and Immunology Department, Saint Louis University School of Medicine, 1100 South Grand Blvd, St. Louis, MO, 63104, USA.
Richard J DiPaoloMolecular Microbiology and Immunology Department, Saint Louis University School of Medicine, 1100 South Grand Blvd, St. Louis, MO, 63104, USA.
Ryan M TeagueMolecular Microbiology and Immunology Department, Saint Louis University School of Medicine, 1100 South Grand Blvd, St. Louis, MO, 63104, USA. ryan.teague@health.slu.edu.

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
NCI NIH HHS P30 CA091842
6 · The paper itself

Abstract

Checkpoint blockade immunotherapy is now a first-line treatment option for patients with melanoma. Despite achieving objective responses in about half of patients, the exact immune mechanisms elicited and those required for therapeutic success have not been clearly identified. Insight into these mechanisms is key for improving outcomes in a broader range of cancer patients. We used a murine melanoma model to track responses by different subsets of tumor-infiltrating lymphocytes (TIL) during checkpoint blockade immunotherapy. Tumors from treated mice had increased frequencies of both CD4

Indexed as

AnimalsAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell Line, TumorComplementarity Determining RegionsCTLA-4 AntigenHumansImmunotherapyLymphocytes, Tumor-InfiltratingMelanoma, ExperimentalMiceMice, Inbred C57BLProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-Cell, alpha-betaAntineoplastic Agents, ImmunologicalComplementarity Determining RegionsCTLA-4 AntigenCTLA4 protein, humanPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-Cell, alpha-betaCheckpoint blockadeImmunotherapyMelanomaT cellTCR diversity

Identifiers

PMID31104075
PMCPMC6939620

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.